Lead Product(s) : TRS02
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the Pre-IND meeting, Tarsier Pharma received FDA's guidance regarding the CMC requirements for slow-release formulation of TRS02. Clarity regarding bridging nonclinical studies requirements and clinical strategy were also obtained.
Product Name : TRS02
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2021
Lead Product(s) : TRS02
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable